PEN
Penumbra Inc
$317.30
▼ 0.2%Updated Today 3:42 PM ET
PEN at a glance — five pillars scored 0–100 from real filed financials.
Overall: Neutral · 52/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▲ Up 26.5% over the last 12 months
Market Cap
$12.53B
P/E
73.25x
Forward P/E (est.)
52.32x
ROE
12.3%
Revenue Growth
17.3%
EPS Growth
323.6%
Profit Margin
11.8%
FCF Yield
0.5%
Debt / Equity
0.02x
ROIC
10.0%
Interest Coverage
108.83x
Current Ratio
6.02x
Dividend Yield
—
Implied Growth (rev. DCF)
7.5%
Rating Score
52/100
Penumbra Inc (PEN) is a large-cap company in the Health Care industry, part of the Health Care sector of the S&P 500, with a market value around $12.53B.
In its latest reported year it generated about $1.40B in revenue and $177.69M in net profit.
Our model rates PEN Neutral (52/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Evidence of durable competitive advantage in the filed financials (10 years of history).
The filed history looks like a business competitors struggle to attack: high and steady margins, revenue that grows through cycles, and strong returns on capital.
64.9% average over the last 3 years
±2.1 pts around 64.6% across 10 years
grew in 9 of the last 9 year-over-year periods
positive in 6 of 10 years
10.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what PEN's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. PEN trades near $317.30, around its 50-day average ($321.64) and 200-day average ($309.55). Price tangled in its moving averages means there is no clear trend — the stock is ranging.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 46 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. PEN's is $2.14 (~0.7% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month PEN found buyers near $314.80 (support) and sellers near $322.65 (resistance); its 52-week range is $221.26–$362.41. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.2× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
4Y CAGR
17.1%
Revenue moved from $263.32M in 2016 to $1.40B in 2025, a 20.4% compound annual growth rate. The most recent year grew a strong 17.3% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
67.1%
Operating Margin
13.5%
Net Margin
12.7%
ROE
12.3%
Penumbra Inc keeps about 11.8% of each sales dollar as net profit, with a 67.1% gross margin and 13.5% operating margin. Return on equity is 12.3% and return on invested capital about 10.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
—
Net Debt
—
Net Debt / EBITDA
—
Debt / Equity
0.02x
Leverage: debt-to-equity is 0.0x, and operating profit covers interest about 108.8x, with a current ratio of 6.0x. That is a conservative balance sheet — a cushion in downturns.
Operating CF
$238.66M
Free Cash Flow
$174.93M
FCF Margin
12.5%
In the latest year Penumbra Inc produced about $238.66M of operating cash flow and $174.93M of free cash flow after capital spending. That is a free-cash-flow yield of about 0.5% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
73.25x
P/S
8.93x
P/B
8.53x
EV / EBITDA
59.45x
PEN trades at 73.3x trailing earnings (about 52.3x on estimated forward earnings), 8.9x sales, and 8.5x book value. Reverse-engineering today's price implies the market expects roughly 7.5% long-term free-cash-flow growth. That is a rich multiple that prices in a lot of future growth.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$159.11
Current price
$317.30
Starting FCF (latest 10-K)
$174.93M
Growth, years 1–5
17.3%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where PEN sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How PEN stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), PEN ranks #42 of 324 by our overall rating. It trades at a premium versus the sector on earnings (73.3x P/E vs. 25.4x median) with a lower return on equity (12.3% vs. 14.1%) and faster revenue growth (17.3% vs. 7.6%).
P/E vs sector
73.3x
median 25.4x
ROE vs sector
12.3%
median 14.1%
Growth vs sector
17.3%
median 7.6%
Sector rank
#42
of 324 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $317.30 today · expected CAGR 7% – 18%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $1.64B | $1.92B | $2.25B | $2.63B | $3.08B |
| Net income | $213.50M | $249.79M | $292.26M | $341.94M | $400.07M |
| EPS | $5.41 | $6.33 | $7.40 | $8.66 | $10.13 |
| Share price (low) | $237.89 | $278.33 | $325.64 | $381.00 | $445.77 |
| Share price (high) | $394.68 | $461.77 | $540.27 | $632.12 | $739.58 |
| CAGR (low–high) | -25% / 24% | -6% / 21% | 1% / 19% | 5% / 19% | 7% / 18% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for PEN:
- Revenue is growing 17.3% a year, a sign of real demand.
- A conservative balance sheet (debt/equity 0.0x) lowers risk.
The case against PEN:
- A rich 73.3x earnings multiple prices in a lot of growth.
- Limited free cash flow at today's price.
Valuation risk — at 73.3x earnings, disappointing results could compress the multiple.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Penumbra Inc is a large-cap health care business still growing nicely, with modest profitability, and a sound balance sheet. It trades at 73.3x earnings, which our model scores Neutral (52/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 21 Wall Street analysts covering PEN recommend (July 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Analysts have turned more cautious over the last three months (-3 pts of buy ratings).
Latest SEC Filings
PEN's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
In the Idea Lab
PEN — frequently asked questions
Is PEN a good stock to buy?
We don't give buy or sell advice. Our model rates Penumbra Inc Neutral (52/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is PEN's rating on The Stocks School?
Penumbra Inc currently scores 52/100 (Neutral) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does PEN's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Penumbra Inc's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for PEN calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this PEN analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell PEN. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.